Serina Therapeutics Announces Dosing of First Parkinson’s Disease Patient in the SER-214 Phase I Trial

Huntsville, AL, January 18th, 2016

Serina Therapeutics, Inc., a pharmaceutical company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has initiated dosing of Parkinson’s disease subjects in the Phase I trial for SER-214.

“We are very pleased to announce that the first subjects have entered the dosing phase of the SER-214 Phase I clinical trial,” stated Randall Moreadith, MD, PhD, President and CEO of Serina Therapeutics. “SER-214 may offer Parkinson’s disease patients an alternative to existing oral agents that do not provide continuous drug delivery, and this Phase I dose-escalation study will establish safety, tolerability and preliminary evaluations of efficacy.”

SER-214 is Serina’s most advanced wholly-owned polymer conjugate. SER-214 is a once-per-week injectable that can be delivered in a standard insulin syringe and results in continuous drug delivery. Continuous dopaminergic stimulation, which would result from continuous drug delivery, has been a long-sought clinical strategy to ameliorate the sometimes disabling consequences of oral treatment with short-acting L-DOPA formulations and dopamine agonists. Information on the SER-214 Phase I trial can be found on ClinicalTrials.gov at the following link: https://clinicalTrials.gov/show/NCT02579473.

Serina’s pipeline programs are aimed primarily at oncology indications that address significant unmet medical needs. In the last three years Serina has executed partnerships with two of the top ten pharmaceutical companies worldwide to employ POZ™ technology.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL. Serina develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology. The founders and executives of Serina were formerly the key principals of Shearwater Polymers, a company whose technology enabled thirteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. In addition to developing its own pipeline of pharmaceutical products for Parkinson’s disease, cancer and post-operative pain, Serina is actively seeking strategic partners for its technology.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com. You may contact Serina Therapeutics at info@serinatherapeutics.com, or Stephanie Green at (256) 327-0566, for additional information about the SER-214 program or partnering opportunities.